US Patent

US9375485 — Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Method of Use · Assigned to Geron Corp · Expires 2033-03-15 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for using telomerase inhibitors to treat individuals with Essential Thrombocythemia (ET).

USPTO Abstract

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Drugs covered by this patent

imetelstat-sodium (IMETELSTAT SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3956`	—	imetelstat-sodium
`U-3956`	—	imetelstat-sodium

Patent Metadata

Patent number: US9375485
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-15
Drug substance claim: No
Drug product claim: No
Assignee: Geron Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.